drugset / Trial / NCT01976143
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors
Timeline
- Start
- 2014-02
- Primary completion
- 2016-06
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etirinotecan Pegol | Other / unclassified | 220 mg/m2 | Intravenous |